VAERS Explorer
Back to explore

Report #2892235

Received Apr 27, 2026

Disabled
A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
OK
Recovered
Not recovered
Vaccinated
Sep 30, 2025
Onset
Oct 20, 2025
Days to onset
20
Hospital days
—

Vaccines (3)

TypeNameManufacturerDoseLotRoute / Site
FLU3INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE)SANOFI PASTEURUNK——
FLUXINFLUENZA (SEASONAL) (NO BRAND NAME)UNKNOWN MANUFACTURERUNK—SC
FLU3INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE)SANOFI PASTEURUNKUT8820AASC

Symptoms (24)

Anti-cyclic citrullinated peptide antibody negativeAntinuclear antibody negativeChronic fatigue syndromeCondition aggravatedDiscomfortGait disturbanceInflammatory marker testRed blood cell sedimentation rate normalRheumatoid factor negativeWalking aid userChronic inflammatory demyelinating polyradiculoneuropathyMuscle disorderAnti-muscle specific kinase antibodyAntiacetylcholine receptor antibody positiveBlood immunoglobulin A decreasedBlood immunoglobulin GBlood immunoglobulin G normalBlood immunoglobulin M normalFatigueImmunoassayIncorrect route of product administrationLight chain analysis decreasedLight chain analysis increasedProtein total normal

Symptom narrative

Extreme effect on muscle/inability to walk correctly; Extreme effect on muscle/inability to walk correctly; extreme fatigue; Initial information received on 10-Apr-2026 regarding an unsolicited valid serious case received from a physician (healthcare professional). This case involves an 80-year-old female patient who experienced extreme effect on muscle /inability to walk correctly and extreme fatigue after receiving Fluzone High Dose. The patient's past medical history included chronic fatigue syndrome for 15 years, mild. On 30-Sep-2025, the patient received a 0.5 mg subcutaneous dose of Fluzone High Dose, Suspension for injection (batch/lot number: UT8820AA) (strength: unknown) via subcutaneous route in an unknown administration site for flu vaccine (Influenza immunisation). Relevant laboratory test results included: Protein electrophoresis - Gamma Globulin 0.7 (low); Kappa/Lambda Light Chain - Kappa 196, Lambda 77 (low); Musk Antibody Test - negative; Acetylcholine Receptor Blocking Antibody - 0.15; Acetylcholine Receptor Modulating Antibody - 31; Protein Total - 6.5; Immunofixation Electrophoresis - no monoclonal proteins detected; Immunoglobulin A - 70; Immunoglobulin G - 775; Immunoglobulin M - 233. The patient experienced extreme effect on muscle /inability to walk correctly (Gait disturbance, onset: 20-Oct-2025, latency: 20 days) and extreme effect on muscle /inability to walk correctly (Muscle disorder, onset: 20-Oct-2025, latency: 20 days). The patient also experienced extreme fatigue (Fatigue, onset: 20-Oct-2025, latency: 20 days). After the vaccine, the chronic fatigue syndrome worsened soon thereafter and has continued to worsen to the date of this report. The patient required the use of a cane and walker due to the inability to walk correctly. Action taken: Not applicable. Corrective treatment: Not reported. Event outcome: Gait disturbance, muscle disorder, and fatigue were not recovered/not resolved/ongoing. Seriousness criteria: Disabling/incapacitating for gait disturbance, muscle disorder, and fatigue.

Current illness

Fatigue

Medical history

Comments: NONE